Immune system activation via tumor antigen release

This term refers to the biological process whereby tumor cell death leads to the release of cancer-specific antigens, which are taken up by antigen-presenting cells (APCs)—primarily dendritic cells—that process and present these antigens to T cells via major histocompatibility complex (MHC) molecules, initiating and amplifying an anti-tumor immune response[1][2][3][4][6]. This cycle, often referenced as the “cancer-immunity cycle,” underpins the mechanism of action for many immunotherapies and cancer vaccines. Key components include the recognition, uptake, and presentation of tumor-associated or tumor-specific antigens, maturation and activation of APCs, T cell priming in lymph nodes, and subsequent trafficking of tumor-specific T cells to the tumor microenvironment to effect cytotoxic tumor cell killing[1][2][3]. Therapies designed to enhance this process often leverage immunogenic cell death (ICD) inducers, oncolytic viruses, radiotherapy, or immune checkpoint inhibitors[4][1]. The process is central to immunotherapy but is not a standalone therapeutic target (like a receptor or enzyme), as it comprises a coordinated sequence of molecular and cellular events. In summary: "Immune system activation via tumor antigen release" is not a canonical molecular target but a process that describes a coordinated response of antigen-presenting cells and T lymphocytes to antigens released by tumor cell death[1][2][3][4]. This process underlies many cancer immunotherapies but should not be cataloged as a discrete molecule, receptor, or drug target.

Other names

Cancer-immunity cycleAntigen release-mediated immune activationImmunogenic cell death-mediated immune response

Induction of immunogenic cell death, activation of antigen-presenting cells, enhancement of T cell priming, release of danger-associated molecular patterns (DAMPs)